

# Ilaria Plantamura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/615716/publications.pdf>

Version: 2024-02-01

20  
papers

659  
citations

840119

11  
h-index

1058022

14  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. <i>Cell Death and Disease</i> , 2016, 7, e2312-e2312.	2.7	232
2	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. <i>Molecular Oncology</i> , 2012, 6, 458-472.	2.1	142
3	miR-9 and miR-200 Regulate PDGFR $\beta$ -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 5562-5572.	0.4	74
4	PDGFR $\beta$ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. <i>Molecular Oncology</i> , 2014, 8, 968-981.	2.1	37
5	miR-205 in Breast Cancer: State of the Art. <i>International Journal of Molecular Sciences</i> , 2021, 22, 27.	1.8	33
6	MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5143.	1.8	30
7	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69649-69665.	0.8	29
8	Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. <i>Cancers</i> , 2021, 13, 3691.	1.7	20
9	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. <i>Oncotarget</i> , 2018, 9, 27920-27928.	0.8	14
10	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. <i>Frontiers in Oncology</i> , 2018, 8, 352.	1.3	13
11	miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. <i>Cells</i> , 2020, 9, 2143.	1.8	13
12	MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2261.	1.7	12
13	What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. <i>Cancer Medicine</i> , 2022, 11, 332-339.	1.3	6
14	Abstract A47: A microRNA signature identifies subtypes of triple-negative breast cancer and reveals miR-342-3p as regulator of a lactate metabolic pathway through silencing monocarboxylate transporter 1. <i>Cancer Research</i> , 2016, 76, A47-A47.	0.4	2
15	Abstract 1068: The promise of miR-205 in HER2+ breast cancer: predicting response to Trastuzumab and overcoming resistance. , 2016, , .		1
16	Pathophysiology roles and translational opportunities of miRNAs in breast cancer. , 2022, , 195-201.		1
17	Abstract 2089: MiR-205 role in triple negative breast cancer. , 2010, , .		0
18	Abstract 4381: MiR-205 and Trastuzumab: Potential as adjuvant therapeutic tool and predictive biomarker. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
19	Abstract A18: miR-9 and miR-200 regulate PDGFR <sup>β</sup> -mediated endothelial differentiation of neoplastic cells in triple-negative breast cancer. , 2016, , .		0
20	Abstract 5437: miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple-negative breast cancer. , 2017, , .		0